Código QR

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...

Descrición completa

Gardado en:
Principais autores: Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2022-06-01
Series:Cells
Assuntos:
breast cancer
pembrolizumab
atezolizumab
durvalumab
immunotherapy
neoadjuvant
Acceso en liña:https://www.mdpi.com/2073-4409/11/12/1857
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares